Company intelligence / Profile preview
Astrogen
Daegu, Taegu-jikhalsi, South Koreaastrogen.org ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 3
01
Overview
AST-001 for Autism Spectrum Disorder is in Phase 3 clinical trials. A multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial started on August 29, 2023, to evaluate the efficacy and safety of AST-001 followed by an open-label extension treatment period in children with Autism Spectrum Disorder[4].
- Therapeutic areas
- PsychiatryRare DiseasesNeurology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
Iktos (collaboration for drug design against a novel Parkinson's disease target)[5]
Beyond the preview
Go deeper on Astrogen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Astrogen.